Van Berkom & Associates Inc. Grows Stock Holdings in Privia Health Group, Inc. $PRVA

Van Berkom & Associates Inc. lifted its position in Privia Health Group, Inc. (NASDAQ:PRVA) by 1.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,844,256 shares of the company’s stock after buying an additional 69,691 shares during the period. Privia Health Group comprises 2.6% of Van Berkom & Associates Inc.’s holdings, making the stock its 10th largest position. Van Berkom & Associates Inc.’s holdings in Privia Health Group were worth $91,147,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Great Lakes Advisors LLC purchased a new position in Privia Health Group during the 3rd quarter worth $4,487,000. ArrowMark Colorado Holdings LLC acquired a new position in Privia Health Group during the 3rd quarter worth $8,750,000. Royce & Associates LP lifted its holdings in shares of Privia Health Group by 54.5% in the 3rd quarter. Royce & Associates LP now owns 607,191 shares of the company’s stock valued at $15,119,000 after purchasing an additional 214,166 shares during the last quarter. Public Sector Pension Investment Board raised its stake in Privia Health Group by 25.9% during the 3rd quarter. Public Sector Pension Investment Board now owns 450,010 shares of the company’s stock valued at $11,205,000 after acquiring an additional 92,507 shares during the last quarter. Finally, Summit Global Investments grew its holdings in shares of Privia Health Group by 273.9% in the 3rd quarter. Summit Global Investments now owns 33,677 shares of the company’s stock worth $839,000 after acquiring an additional 24,670 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Privia Health Group Stock Performance

Shares of Privia Health Group stock opened at $24.24 on Tuesday. The company has a fifty day moving average of $22.59 and a 200-day moving average of $23.37. Privia Health Group, Inc. has a 52-week low of $18.77 and a 52-week high of $26.51. The stock has a market capitalization of $3.05 billion, a price-to-earnings ratio of 142.59, a price-to-earnings-growth ratio of 1.55 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.04 by $0.21. The company had revenue of $541.17 million for the quarter, compared to the consensus estimate of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. Privia Health Group’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.21 EPS. On average, equities research analysts forecast that Privia Health Group, Inc. will post 0.37 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on PRVA. Jefferies Financial Group reaffirmed a “buy” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, February 26th. Truist Financial upped their price target on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Canaccord Genuity Group raised their price objective on shares of Privia Health Group from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Citigroup reduced their price target on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, March 3rd. Finally, Royal Bank Of Canada began coverage on shares of Privia Health Group in a research note on Friday, January 9th. They issued an “outperform” rating and a $31.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.31.

Insiders Place Their Bets

In other news, CFO David Mountcastle sold 5,566 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.85, for a total transaction of $116,051.10. Following the completion of the sale, the chief financial officer owned 214,847 shares in the company, valued at $4,479,559.95. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Parth Mehrotra sold 26,509 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $22.11, for a total transaction of $586,113.99. Following the completion of the transaction, the chief executive officer owned 555,443 shares in the company, valued at approximately $12,280,844.73. This trade represents a 4.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 247,757 shares of company stock worth $5,636,639. Corporate insiders own 5.70% of the company’s stock.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.